{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:35:11Z","timestamp":1785771311268,"version":"3.56.0"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this all\u2010case post\u2010marketing study was to evaluate the real\u2010world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir\/pibrentasvir (G\/P) in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational post\u2010marketing surveillance study was conducted at 67 medical institutions from 2019 to 2024. Eligible patients were aged 3 to &lt; 18\u00a0years (children: 3 to\u00a0&lt;\u00a012\u00a0years; and adolescents: 12 to\u00a0&lt;\u00a018\u00a0years), with chronic Hepatitis C virus (HCV) infection with or without compensated cirrhosis. Patients were treated with G\/P for 8 or 12\u00a0weeks and followed\u2010up for 24\u00a0weeks. The primary endpoints included adverse drug reactions (ADRs) and serious adverse events (AEs). The secondary endpoints included sustained virologic response at 12\u00a0weeks after treatment completion (SVR12).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>None of the 103 patients had compensated cirrhosis or prior exposure to direct\u2010acting antiviral therapy; the majority had either genotype 1\/serogroup 1 or genotype 2\/serogroup 2 HCV infections. All children (100.0%, 26\/26) and most adolescents (97.4%, 75\/77) completed G\/P treatment; the two adolescents discontinued owing to pregnancy\/transfer and insufficient drug administration. No AEs led to treatment discontinuation. No serious AEs were observed. ADRs did not occur in children (0.0%, 0\/26) but occurred in nine adolescents (11.7%, 9\/77). Post\u2010treatment virologic failure (relapse) was observed in one child and no adolescents, and the remaining children (96.2%, 25\/26) and all adolescents (100%, 66\/66) achieved SVR12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our real\u2010world findings suggest that G\/P is a potentially safe and efficacious treatment option for children and adolescents with chronic HCV infection. Further data on patients with compensated cirrhosis and long\u2010term post\u2010SVR outcomes would be valuable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hepr.70173","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:15:07Z","timestamp":1776489307000},"page":"1202-1212","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Glecaprevir\/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All\u2010Case Post\u2010Marketing Surveillance in Japan"],"prefix":"10.1111","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-7068","authenticated-orcid":false,"given":"Tatsuki","family":"Mizuochi","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Child Health Kurume University School of Medicine  Kurume Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-1163","authenticated-orcid":false,"given":"Katsuyoshi","family":"Kawana","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-2685","authenticated-orcid":false,"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5176-8493","authenticated-orcid":false,"given":"Eri","family":"Iwashita","sequence":"additional","affiliation":[{"name":"AbbVie GK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-8195","authenticated-orcid":false,"given":"Itaru","family":"Iwama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Saitama Children's Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Abukawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Miyagi Children's Hospital  Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2715","authenticated-orcid":false,"given":"Hitoshi","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Wakayama Medical University  Wakayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"World Health Organization. \u201cHepatitis C \u201d (2024).https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010c."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0168\u20108278(15)31458\u20106"},{"key":"e_1_2_12_4_1","unstructured":"H.RazaviandM.El\u2010Sayed \u201cUpdated Global Estimate of HCV Infection in the Pediatric Population \u201d\u00a0(2016).http:\/\/cdafound.org\/content\/Downloads\/Pediatric%20Prevalence%20161201.pdf."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(19)30046\u20109"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100428"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000324525"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535\u2010017\u20101351\u20100"},{"key":"e_1_2_12_9_1","volume-title":"The Committee for the Development of Clinical Practice Guidelines for Hepatitis","author":"The Japan Society of Hepatology","year":"2025"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14032"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201025519\u20101"},{"issue":"21","key":"e_1_2_12_12_1","article-title":"Infectious Disease Weekly Report","volume":"13","author":"Ministry of Health Labour and Welfare\/National Institute of Infectious Diseases","year":"2011","journal-title":"Infectious Disease Surveillance"},{"key":"e_1_2_12_13_1","unstructured":"World Health Organization. \u201cWorld Hepatitis Day 2025. Hepatitis: Let\u2019s Break It down \u201d. Accessed 19 Aug 2025.https:\/\/www.who.int\/campaigns\/world\u2010hepatitis\u2010day\/2025."},{"key":"e_1_2_12_14_1","unstructured":"AbbVie GK. \u201cMAVIRET\u24c7(glecaprevir and pibrentasvir) Combination tablets [package insert] Revised \u201d [in Japanese]. Accessed 15 July 2025.https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112130_6250113F1021_1_07."},{"key":"e_1_2_12_15_1","unstructured":"AbbVie GK. \u201cMAVIRET\u24c7(glecaprevir and pibrentasvir) Combination granules for pediatric use [package insert] Revised \u201d [in Japanese]. Accessed 15 July 2025.https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112130_6250113D1020_1_03."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31841"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30840"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.70045"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16180"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535\u2010023\u201001968\u2010x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.70004"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0016\u20105085(98)70032\u20100"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22094"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360\u2010020\u201000412\u20107"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.63.120"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.12.011"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20104642(25)00028\u20108"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.70173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hepr.70173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.70173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:43:08Z","timestamp":1785768188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hepr.70173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/hepr.70173"],"URL":"https:\/\/doi.org\/10.1111\/hepr.70173","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}